Donanemab-AZBT

AlzeCure Pharma CEO Martin Jonsson and CSO Johan Sandin.\n Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer\'s disease from AlzeCure Pharma for up to $1 billion biobucks.Lilly is obtaining the rights to the small-molecule treatment for $10 million upfront, according to a June 9 release. The treatment aims to reduce the production of the harmful amyloid-beta protein Aβ42.Aβ42 forms the building blocks of amyloid plaques found in the brains of patients with Alzheimer\'s disease. In addition to reducing the production of Aβ42, ACD860 is designed to increase benign proteins such as Aβ37 and Aβ38, which may also reduce Aβ42 levels and harmful plaque buildup in the brain.The benefits of the drug may extend beyond treating Alzheimer\'s disease, AlzeCure CEO Martin Jönsson said in a statement. “In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer’s disease,” he explained.Development and commercial milestones could exceed $1 billion for the Swedish biotech, while tiered mid-single-digit royalties on sales have the potential to increase the deal\'s value even further, according to the release.Lilly has been active in Alzheimer’s over the past few years as it searches for the next breakthrough following its success in obesity. Lilly\'s Kisunla is the company\'s primary Alzheimer\'s asset, which managing neurology analyst at GlobalData, Philippa Salter, said could reach $3.8 billion in sales by 2033. The Alzheimer\'s market is expected to increase in value eightfold by 2034, according to GlobalData.But Kisunla rise has not been without controversy. In 2024, The New York Times reported that Lilly failed to tell patients involved in a Kisunla trial the results of genetic tests used to identify those at higher risk of developing Alzheimer\'s, a decision some experts questioned.Lilly is not resting on the laurels of Kisunla, which was approved in 2024, and has remained busy both adding to and culling assets from its Alzheimer\'s pipeline. Last year, the company dropped eperognastat, an oral O-GlcNAcase anti-tau agent, after the candidate failed to slow clinical decline in patients with early symptomatic Alzheimer\'s disease in a Phase 2 trial.In April, Lilly paid $12.5 million to Swiss biotech AC Immune to expand their Alzheimer\'s disease collaboration. The deal followed an $81 million upfront payment in 2018 for a small molecule designed to inhibit tau aggregation in Alzheimer\'s patients.

Eli Lilly has agreed to license global rights to Alzstatin ACD680, a preclinical small-molecule gamma-secretase modulator for Alzheimer’s disease, from Sweden-based AlzeCure Pharma AB (STO: ALZCUR), in a deal worth up to USD 1 billion excluding royalties. The transaction gives Lilly worldwide development and commercialization rights to the compound and adds a mechanistically distinct amyloid-targeting approach to a neuroscience portfolio that already includes the approved anti-amyloid antibody donanemab (Kisunla). Under the terms, AlzeCure receives a USD 10 million upfront payment, tiered mid-single-digit royalties on net sales, and development and commercial milestones that could push the total deal value beyond USD 1 billion. Specific milestone triggers and individual payment amounts were not disclosed. The transaction is subject to closing conditions including approval by Swedish authorities under foreign direct investment regulations. Deal context Alzstatin ACD680 (AC-0027875) is a small-molecule gamma-secretase modulator (GSM) described by AlzeCure as capable of reducing production of the toxic amyloid-beta peptide Aβ42 while simultaneously increasing shorter, less aggregation-prone variants Aβ37 and Aβ38. The compound works by allosterically shifting the cleavage preference of the gamma-secretase enzyme complex rather than blocking the enzyme outright — a design intended to preserve Notch signaling and avoid the severe toxicities that caused earlier gamma-secretase inhibitors such as semagacestat to fail in Phase III. The mechanistic distinction from Lilly’s existing portfolio is material. Donanemab clears amyloid plaques that have already formed; ACD680 is positioned to reduce Aβ42 production upstream, before aggregation occurs. AlzeCure has described the Alzstatin program as potentially suited to both disease modification and prevention, though no clinical data have been generated. The compound remains preclinical, and Lilly will assume responsibility for clinical development and commercialization following closing. The Alzstatin platform has a documented genetic rationale: AlzeCure’s chief scientific officer noted in the announcement that gamma-secretase modulators carry a strong genetic link to Alzheimer’s disease, referencing the well-established connection between presenilin mutations — which alter gamma-secretase cleavage — and familial Alzheimer’s. Industry and transaction context The USD 10 million upfront payment is modest relative to recent Alzheimer’s-focused licensing transactions, reflecting the asset’s preclinical stage. By comparison, when Rockville, Maryland-based SciNeuro Pharmaceuticals licensed an amyloid-beta antibody program to Novartis in January 2026, SciNeuro received USD 165 million upfront against a total potential value of up to USD 1.5 billion — a deal involving a more advanced antibody program with blood-brain barrier shuttle technology. Lilly has been an active acquirer of CNS and neurodegenerative disease assets across modalities. In April 2026, Lilly amended its Tau collaboration with AC Immune, paying a CHF 10 million (USD 12.5 million) upfront fee to extend coverage to new oral small-molecule Tau aggregation inhibitors. The structural choice to license a preclinical GSM rather than an antibody is notable given the crowded anti-amyloid antibody landscape. The approvals of lecanemab and donanemab — both anti-amyloid biologics requiring infusion — have validated the amyloid hypothesis but left room for differentiated approaches, particularly oral small molecules that could address earlier-stage or prevention-oriented populations. The GSM class has not produced an approved drug, but the mechanistic rationale has been rehabilitated following the Notch-toxicity failures of first-generation gamma-secretase inhibitors, and the AlzeCure deal suggests Lilly sees the approach as worth clinical evaluation. For AlzeCure, the transaction represents the first major out-licensing of its Alzstatin platform and provides non-dilutive capital and validation for a company whose market capitalization on Nasdaq First North has remained small. AlzeCure retains its NeuroRestore and Painless platforms, which include separate CNS and pain assets not covered by the Lilly agreement. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.